Delivery of erythropoietin with a needleless injection system during hemodialysis maintains plasma levels

ASAIO Journal

Volumn 47, Issue 6, 2001, Pages 608-610

  Petersen, Jeffrey ^a,b   Jani, Alkesh ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; HEMODIALYZERS; NEEDLES;

NEEDLELESS INJECTION SYSTEMS;

DIALYSIS;

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALE; NEEDLE; SYRINGE;

EID: 0035164507     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-200111000-00007     Document Type: Article

References (6)

1. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III Multicenter Clinical Trial
2. Anemia management of adult hemodialysis patients in the US results from the 1997 ESRD Core Indicators Project
3. The site of injection affects erythropoietin levels during dialysis
4. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease
5. Trends in use, cost, and outcomes of human recombinant erythropoietin, 1989-98